AZD8701
Phase 1Small molecule
AstraZenecaAZD8701 is one of 24 small molecule programs targeting Lung Carcinoma. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Lung Carcinoma
#DrugCompanyPhaseTrials
1Afinitor
NovartisApproved
Iressa
AstraZenecaApproved
Lumakras
AmgenApproved
Chantix
PPrism Pharmaceuticals
Approved
Navelbine
PPierre Fabre Medicament
Approved
Aurlumyn
BBTG International Inc.
Approved
Paraplatin
AAvyxa
Phase 3
Ilaris
NovartisPhase 2
Taxotere
AAvyxa
Phase 2
Caprelsa
GGenzyme, a Sanofi Company
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AZD8701. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company